News

News and Press Releases
Our Research Approach Cystic Fibrosis Foundation Invests an Additional $5 Million in BiomX

Funding will support a Phase 2b trial of phage therapy for chronic Pseudomonas aeruginosa lung infections.

| 2 min read
Our Research Approach Cystic Fibrosis Foundation Invests More Than $6.6 Million in Additional Funding in Sionna Therapeutics

The funding will help support research into the development of potential new modulator therapies for people with cystic fibrosis with an F508del mutation.

| 2 min read
Our Research Approach Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF

Prime Medicine’s prime editing technology has the potential to bring genetic therapies to all people with cystic fibrosis, ultimately paving the way to a cure.

| 4 min read
Our Research Approach CF Foundation Invests up to $5M in Clarametyx Biosciences to Develop a New Anti-Bacterial Therapy 

Clarametyx’s novel therapy aims to disrupt bacterial biofilms, one of the primary causes of antibiotic resistance, thereby potentially increasing the effectiveness of existing treatments in fighting a wide range of bacterial infections, including those commonly affecting people with CF.

| 2 min read
Our Research Approach CF Foundation Invests Up to $3 Million in ViaNautis Bio to Explore a New Method to Deliver Genetic Therapies to People With CF

ViaNautis’ non-viral delivery mechanism, polyNaut®, aims to improve delivery of genetic therapies to the cells of people with CF. 

| 2 min read
Diversity, Equity, and Inclusion | Our Research Approach CF Foundation Awards Advance Improvements in CF Newborn Screening

Since 2011, the Foundation has awarded $2.5 million across 35 different projects to improve cystic fibrosis newborn screening across the country.

| 4 min read
Our Research Approach CF Foundation Invests Up to $9 Million in Arcturus Therapeutics to Develop a Messenger RNA Therapy

The Cystic Fibrosis Foundation is providing additional funding to Arcturus Therapeutics to develop an inhaled messenger RNA therapy for CF that provides lung cells with the correct instructions to make functional cystic fibrosis transmembrane conductance regulator protein. The funding brings our total commitment to Arcturus to approximately $25 million.

| 3 min read
Our Research Approach CF Foundation Invests Up to $2 Million in Nosis Bio for Potential Gene Therapy Delivery Technology

Nosis Bio, an inaugural winner of the Foundation’s Golden Ticket Competition, receives funding to further explore design of novel ligands, which are specialized molecules that could help more precise targeting of relevant cells in the lung. 

| 3 min read
Our Research Approach CF Foundation Provides Up to $3.9M to TB Alliance to Further Develop an NTM Drug

The Cystic Fibrosis Foundation is providing additional funds to TB Alliance to advance the development of a compound that could be used to treat infections caused by nontuberculous mycobacteria.

| 2 min read
Our Research Approach Cystic Fibrosis Foundation Commits Up to $15.5M in Additional Funding for Potential Enzyme Therapy

Funding will support clinical trials for therapy that could help improve digestion in people with CF

| 3 min read